应用受激拉曼组织学与深度学习术中快速检测原发性中枢神经系统淋巴瘤并与常见中枢神经系统肿瘤鉴别
研究将受激拉曼组织学(SRH)与深度学习结合,开发RapidLymphoma流程,术中3分钟内生成虚拟H&E样图像。在前瞻性国际多中心队列(n=160)中总体平衡准确率97.81%±0.91,检测PCNSL非劣于冰冻切片分析(100% vs 77.77%)。
要点
- RapidLymphoma术中检测PCNSL的平衡准确率达97.81%±0.91。
- 检测PCNSL非劣于冰冻切片分析(100% vs 77.77%)。
- 可在3分钟内提供视觉反馈,辅助快速临床决策。
核心结论
- RapidLymphoma对术中检测PCNSL及与其他CNS病变的鉴别可靠且有效,3分钟内提供视觉反馈,有助于快速临床决策和后续治疗策略规划。
研究设计与样本
- 研究采用便携式拉曼散射显微镜对术中未处理、无标记组织样本成像,在3分钟内生成虚拟H&E样图像。
- 基于自监督学习策略开发RapidLymphoma深度学习流程,用于检测PCNSL、与其他CNS病变鉴别并测试诊断性能。
- 训练集为54 000张SRH图像块,来源于手术切除和立体定向引导活检,涵盖多种CNS肿瘤性/非肿瘤性病变。
- 训练和测试数据来自4个国际三级医疗中心,最终组织病理学诊断作为参考标准。
- 在前瞻性国际多中心队列及2个额外独立测试队列中验证诊断性能。
主要发现
- 前瞻性测试队列纳入PCNSL和非PCNSL病变(n=160),RapidLymphoma总体平衡准确率为97.81%±0.91。
- 检测PCNSL方面,RapidLymphoma非劣于冰冻切片分析(100% vs 77.77%)。
- 额外测试队列(n=420)鉴别IDH野生型弥漫性胶质瘤与PCNSL的平衡准确率为95.44%±0.74。
- 额外测试队列(n=59)鉴别各种脑转移瘤与PCNSL的平衡准确率为95.57%±2.47。
- 可视化热力图显示RapidLymphoma能够检测类别特异性的组织形态学关键特征。
关键数值与推荐
- RapidLymphoma检测PCNSL的总体平衡准确率为97.81%±0.91(前瞻性测试队列n=160)。
- RapidLymphoma检测PCNSL非劣于冰冻切片分析(100% vs 77.77%)。
- 鉴别IDH野生型弥漫性胶质瘤与PCNSL的平衡准确率为95.44%±0.74(n=420)。
- 鉴别各种脑转移瘤与PCNSL的平衡准确率为95.57%±2.47(n=59)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate intraoperative diagnosis is crucial for differentiating between primary central nervous system (CNS) lymphoma (PCNSL) and other CNS entities, guiding surgical decision-making, but represents significant challenges due to overlapping histomorphological features, time constraints, and differing treatment strategies. We combined stimulated Raman histology (SRH) with deep learning to address this challenge. METHODS: We imaged unprocessed, label-free tissue samples intraoperatively using a portable Raman scattering microscope, generating virtual H&E-like images within <3 min. We developed a deep learning pipeline called RapidLymphoma based on a self-supervised learning strategy to (1) detect PCNSL, (2) differentiate from other CNS entities, and (3) test the diagnostic performance in a prospective international multicenter cohort and 2 additional independent test cohorts. We trained on 54 000 SRH patch images sourced from surgical resections and stereotactic-guided biopsies, including various CNS neoplastic/nonneoplastic lesions. Training and test data were collected from 4 tertiary international medical centers. The final histopathological diagnosis served as ground truth. RESULTS: In the prospective test cohort of PCNSL and non-PCNSL entities (n = 160), RapidLymphoma achieved an overall balanced accuracy of 97.81% ± 0.91, non-inferior to frozen section analysis in detecting PCNSL (100% vs. 77.77%). The additional test cohorts (n = 420, n = 59) reached balanced accuracy rates of 95.44% ± 0.74 and 95.57% ± 2.47 in differentiating IDH-wildtype diffuse gliomas and various brain metastasis from PCNSL. Visual heatmaps revealed RapidLymphoma's capabilities to detect class-specific histomorphological key features. CONCLUSIONS: RapidLymphoma proves reliable and valid for intraoperative PCNSL detection and differentiation from other CNS entities. It provides visual feedback within 3 min, enabling fast clinical decision-making and subsequent treatment strategy planning.
引用
- Reinecke D, Maarouf N, Smith A, et al. Fast intraoperative detection of primary central nervous system lymphoma and differentiation from common central nervous system tumors using stimulated Raman histology and deep learning. Neuro Oncol. 2025. PMID: 39673805. doi:10.1093/neuonc/noae270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。